Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rEECur trial in recurrent or primary refractory Ewing sarcoma
NL-OMON60720Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Dec 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, ifosfamide, lenvatinib, carboplatin and etoposide in Ewing sarcoma and Ewing-like sarcoma (4 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival time. Started Dec 2017; status: recruiting.
02
Drugs
irinotecanifosfamidelenvatinibcarboplatinetoposide
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on NL-OMON60720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60720.